At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 374 enrolled
Drug / intervention
VR506 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Placebo-controlled, Parallel Group, Study to Evaluate the Efficacy and Safety of VR506 Inhaled From a New Inhaler in Adolescent and Adult Subjects With Asthma
In Brief
A Phase 3 clinical trial evaluating VR506 and Placebo for Asthma. Completed, enrolled 374 participants across 82 sites in 5 countries.
Detailed Summary
The purpose of the study is to evaluate the clinical efficacy of three doses of VR506 delivered via a new dry powder inhaler for the treatment of asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesPhilippines, Poland, Romania, Ukraine, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2011
First PostedNov 2011
Primary CompletionMay 2013
TodayJul 2026
First PostedNov 16, 2011
Enrollment StartOct 1, 2011
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 14.6 years ago
Interventions
VR506drug
VR506 inhalation powder delivered via a new dry powder inhaler
Placebodrug
Placebo delivered via a new dry powder inhaler